Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-015877
Filing Date
2021-11-15
Accepted
2021-11-15 08:30:44
Documents
55
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q blph-20210930x10q.htm   iXBRL 10-Q 1165365
2 EX-31.1 blph-20210930xex31d1.htm EX-31.1 9859
3 EX-31.2 blph-20210930xex31d2.htm EX-31.2 9384
4 EX-32 blph-20210930xex32.htm EX-32 9157
  Complete submission text file 0001558370-21-015877.txt   5109301

Data Files

Seq Description Document Type Size
5 EX-101.SCH blph-20210930.xsd EX-101.SCH 38005
6 EX-101.CAL blph-20210930_cal.xml EX-101.CAL 30012
7 EX-101.DEF blph-20210930_def.xml EX-101.DEF 163145
8 EX-101.LAB blph-20210930_lab.xml EX-101.LAB 349560
9 EX-101.PRE blph-20210930_pre.xml EX-101.PRE 275944
10 EXTRACTED XBRL INSTANCE DOCUMENT blph-20210930x10q_htm.xml XML 867137
Mailing Address 184 LIBERTY CORNER ROAD, SUITE 302 WARREN NJ 07059
Business Address 184 LIBERTY CORNER ROAD, SUITE 302 WARREN NJ 07059 908-574-4770
Bellerophon Therapeutics, Inc. (Filer) CIK: 0001600132 (see all company filings)

EIN.: 473116175 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36845 | Film No.: 211406579
SIC: 2834 Pharmaceutical Preparations